Stratos Wealth Partners LTD. Sells 25,840 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Stratos Wealth Partners LTD. lessened its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 7.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 310,000 shares of the company's stock after selling 25,840 shares during the period. Stratos Wealth Partners LTD. owned 0.57% of Zevra Therapeutics worth $2,322,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its holdings in Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock valued at $30,441,000 after buying an additional 3,001,000 shares in the last quarter. AIGH Capital Management LLC acquired a new position in Zevra Therapeutics in the 4th quarter valued at $6,577,000. Barclays PLC grew its holdings in Zevra Therapeutics by 402.9% in the 4th quarter. Barclays PLC now owns 289,688 shares of the company's stock valued at $2,416,000 after buying an additional 232,089 shares in the last quarter. Altium Capital Management LLC grew its holdings in Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock valued at $15,429,000 after buying an additional 150,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after purchasing an additional 144,256 shares in the last quarter. Institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Price Performance

Shares of ZVRA stock traded up $0.26 on Monday, hitting $12.79. 2,260,923 shares of the company's stock were exchanged, compared to its average volume of 722,109. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. Zevra Therapeutics, Inc. has a 12 month low of $5.45 and a 12 month high of $13.40. The stock has a market cap of $699.36 million, a P/E ratio of -6.73 and a beta of 1.97. The company has a 50 day moving average of $9.06 and a 200 day moving average of $8.20.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same period in the prior year, the company earned ($0.40) EPS. On average, equities research analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZVRA. Cantor Fitzgerald increased their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday. HC Wainwright began coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 target price on the stock. Wall Street Zen raised Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday. Finally, Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $23.71.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.